CoChat

Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2

Open access
Voutsadakis, Ioannis A. · 2007 · Journal of Cellular and Molecular Medicine
Cited by 74

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Introduction APC and the Wnt pathway K‐ras initiated pathways The TGF‐β pathway P53 and its functional regulation and dysregulation in colorectal cancer The ubiquitin‐proteasome system (UPS) The ubiquitin‐proteasome system in apoptosis and the cell cycle Proteasome inhibition in colorectal carcinoma Cox‐2 in colorectal cancer Cox‐2 and lipid metabolism in colorectal cancer Cox‐independent anti‐carcinogenic effects of Cox inhibitors Combined Cox and proteasome inhibition in colorectal cancer Pathways of the molecular pathogenesis of colorectal carcinoma have been extensively studied and molecular lesions during the development of the disease have been revealed. High up in the list of colorectal cancer lesions are APC (adenomatous polyposis coli), K‐ras, Smad4 (or DPC4‐deleted in pancreatic cancer 4) and p53 genes. All these molecules are part of important pathways for the regulation of cell proliferation and apoptosis and as a result perturbation of these processes lead to carcinogenesis. The ubiquitin–proteasome system (UPS) is comprised of a multi‐unit cellular protease system that regulates several dozens of cell proteins after their ligation with the protein ubiquitin. Given that among these proteins are regulators of the cell cycle, apoptosis, angiogenesis, adhesion and cell signalling, this system plays a significant role in cell fate and carcinogenesis. UPS inhibition has been found to be a pre‐requisite for apoptosis and is already clinically exploited with the proteasome inhibitor bortezomib in multiple myeloma. Cyclooxygenase‐2 (Cox‐2) is the inducible form of the enzyme that metabolizes the lipid arachidonic acid to prostaglandin H 2, the first step of prostaglandins production. This enzyme is up‐regulated in colorectal cancer and in several other cancers. Inhibition of Cox‐2 by aspirin and other non‐steroidal anti‐inflammatory drugs (NSAIDs) has been found to inhibit proliferation of colorectal cancer cells and in epidemiologic studies has been shown to reduce colon polyp formation in genetically predisposed populations and in the general population. NSAIDs have also Cox‐independent anti‐proliferative effects. Targeted therapies, the result of increasingly understanding carcinogenesis in the molecular level, have entered the field of anti‐neoplastic treatment and are used by themselves and in combination with chemotherapy drugs. Combinations of targeted drugs have started also to be investigated. This article reviews the molecular pathogenesis of colorectal cancer, the roles of UPS and Cox‐2 in it and puts forward a rational for their combined inhibition in colorectal cancer treatment.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1582-4934.2007.00032.x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 74

Metadata

Authors
Voutsadakis, I. A.
Venue
Journal of Cellular and Molecular Medicine
Publisher
Wiley
Published
2007-03
Volume
11
Issue
2
Pages
252-285
ISSN
  • 1582-1838 (ISSN-L)
  • 1582-4934
OpenAlex
W2120558703
Cited by
74
References
15
FWCI
2.04
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2. https://app.cochat.ai/papers/10.1111/j.1582-4934.2007.00032.x
The paper
Voutsadakis, I. A. (2007). Pathogenesis of colorectal carcinoma and therapeutic implications: the roles of the ubiquitin–proteasome system and Cox‐2. Journal of Cellular and Molecular Medicine. https://doi.org/10.1111/j.1582-4934.2007.00032.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.